Company Description
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States.
The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.
It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea.
The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency.
Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform.
The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015.
Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
| Country | United States |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 186 |
| CEO | Dr. Lindsay Allan Rosenwald |
Contact Details
Address: 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 United States | |
| Phone | 781-652-4500 |
| Website | fortressbiotech.com |
Stock Details
| Ticker Symbol | FBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001429260 |
| CUSIP Number | 34960Q109 |
| ISIN Number | US34960Q3074 |
| Employer ID | 20-5157386 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lindsay Allan Rosenwald | Executive Chairman, President and Chief Executive Officer |
| David Jin | Chief Financial Officer and Head of Corporate Development |
| Michael S. Weiss Esq. | Executive Vice Chairman of Strategic Development and Director |
| Samuel Berry | General Counsel and Corporate Secretary |
| Dr. George C. Avgerinos | Senior Vice President of Biologics Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | 4 | Statement of changes in beneficial ownership of securities |
| Apr 5, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 5, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 5, 2024 | 424B3 | Prospectus |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 4 | Statement of changes in beneficial ownership of securities |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 26, 2024 | 8-K | Current Report |
| Jan 3, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |